These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29088761)

  • 1. The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.
    Kim HK; Ha SY; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
    Oncotarget; 2017 Sep; 8(43):73974-73980. PubMed ID: 29088761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
    Yoon SE; Kim JH; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
    J Cancer; 2019; 10(14):3140-3144. PubMed ID: 31289584
    [No Abstract]   [Full Text] [Related]  

  • 3. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall.
    Vyas M; Tang LH; Rekhtman N; Klimstra DS
    Am J Surg Pathol; 2021 Jan; 45(1):25-34. PubMed ID: 33177340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
    Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
    PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.
    Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
    Cancer Cytopathol; 2018 May; 126(5):326-335. PubMed ID: 29451738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
    Kim ST; Ha SY; Lee S; Ahn S; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim KM; Park YS
    J Cancer; 2016; 7(5):484-9. PubMed ID: 26958083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grading of Neuroendocrine Carcinomas: Correlation of
    Liverani C; Bongiovanni A; Mercatali L; Foca F; Pieri F; De Vita A; Spadazzi C; Miserocchi G; Recine F; Riva N; Nicolini S; Severi S; Martinelli G; Ibrahim T
    Dis Markers; 2018; 2018():6878409. PubMed ID: 30627226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
    Artale S; Giannetta L; Cerea G; Maggioni D; Pedrazzoli P; Schiavetto I; Napolitano M; Veronese S; Bramerio E; Gambacorta M; Vanzulli A; Pisconti S; Pugliese R; Siena S
    Anticancer Res; 2005; 25(6C):4463-9. PubMed ID: 16334127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma.
    Shen H; Gu Y; Fang Y; Xu T; Xu Y; Wu X; Shu Y; Ma P
    J Gastrointest Oncol; 2024 Jun; 15(3):921-930. PubMed ID: 38989422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
    De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
    J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
    Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
    J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
    Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
    Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroenteropancreatic high-grade neuroendocrine carcinoma.
    Sorbye H; Strosberg J; Baudin E; Klimstra DS; Yao JC
    Cancer; 2014 Sep; 120(18):2814-23. PubMed ID: 24771552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.